Prognostic Histopathological Parameters and Their Correlation in the Clinical-Pathological Examination of Melanomas
References
- Antohe M, Coman A, Turcu G, et al. The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients. Med Pharm Rep. 2022;95(3):229-235.
- Rashed H, Flatman K, Bamford M, Teo KW, Saldanha G. Breslow density is a novel prognostic feature in cutaneous malignant melanoma. Histopathology. 2017;70(2):264-272. doi:10.1111/his.13060
- Grande Sarpa H, Reinke K, Shaikh L, et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol. 2006;30(11):1396-1400. doi:10.1097/01.pas.0000213262.61855.7d
- Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database [published correction appears in J Clin Oncol. 2011 Jul 20;29(21):2949]. J Clin Oncol. 2011;29(16):2199-2205. doi:10.1200/JCO.2010.31.5812
- Tian J, Quek C. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses. Int J Mol Sci. 2024;25(8):4243. Published 2024 Apr 11. doi:10.3390/ijms25084243
- Garutti M, Bruno R, Polesel J, Pizzichetta MA, Puglisi F. Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis. Heliyon. 2024;10(12):e32433. Published 2024 Jun 6. doi:10.1016/j.heliyon.2024.e32433
- Scolyer RA, Rawson RV, Gershenwald JE, Ferguson PM, Prieto VG. Melanoma pathology reporting and staging. Mod Pathol. 2020;33(Suppl 1):15-24. doi:10.1038/s41379-019-0402-x
- Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel). 2023;15(4):1106. Published 2023 Feb 9. doi:10.3390/cancers15041106
- Shah V, Panchal V, Shah A, Vyas B, Agrawal S, Bharadwaj S. Immune checkpoint inhibitors in metastatic melanoma therapy (Review). Med Int (Lond). 2024;4(2):13. Published 2024 Feb 9. doi:10.3892/mi.2024.137
- Bobos M. Histopathologic classification and prognostic factors of melanoma: a 2021 update. Ital J Dermatol Venerol. 2021;156(3):300-321. doi:10.23736/S2784-8671.21.06958-3
- Falcone I, Conciatori F, Bazzichetto C, et al. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers (Basel). 2020;12(10):2870. Published 2020 Oct 6. doi:10.3390/cancers12102870
- Gogas H, Eggermont AM, Hauschild A, et al. Biomarkers in melanoma. Ann Oncol. 2009;20 Suppl 6(Suppl 6):vi8-vi13. doi:10.1093/annonc/mdp251
- Zito PM, Scharf R. Melanoma of the Head and Neck. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513248/
- Cerkauskaite D, Dulskas A, Vincerzevskiene I, Tikuisis R, Urbonas V. Changing epidemiology and age-specific incidence of cutaneous malignant melanoma in Lithuania: an analysis of national cancer registration data by gender and anatomical site, 1991–2015. Contemporary Oncology/Wspołczesna Onkologia. 2022;26(4):289-293. doi:10.5114/wo.2023.124920.
- Costa SR, Horta SH, Henriques AC. Popliteal lymphadenectomy for treating metastatic melanoma: case report. Sao Paulo Med J. 2008;126(4):232-235. doi:10.1590/s1516-31802008000400009
- Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021;51(5):671-674. doi:10.1093/jjco/hyab022
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. Eur J Cancer. 2025;215:115153. doi:10.1016/j.ejca.2024.115153
- Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N et.al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics— Update 2024. Eur J Cancer. 2025;215:115152. doi:10.1016/j.ejca.2024.115152.
- Jansen J, Garmyn M, Guvenc C. The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review. Int J Mol Sci. 2024;25(12):6433. Published 2024 Jun 11. doi:10.3390/ijms25126433
- Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clin Cancer Res. 2017;23(17):5024-5033. doi:10.1158/1078-0432.CCR-16-0698
- Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother. 2010;33(6):570-590. doi:10.1097/CJI.0b013e3181e032e8
- Barber K, Searles GE, Vender R, Teoh H, Ashkenas J. Nonmelanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery. 2015;19(3):216-226. doi:10.1177/1203475415576465
- Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015;177-186. doi:10.14694/EdBook_AM.2015.35.177
DOI: https://doi.org/10.2478/orvtudert-2024-0013 | Journal eISSN: 2537-5059 | Journal ISSN: 1453-0953
Language: English
Page range: 146 - 156
Published online: May 21, 2026
Published in print: Dec 1, 2024
Published by: Transylvanian Museum Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
© 2026 Madaras Tímea, Nagy Előd-Ernő, Trâmbițaș Cristian, published by Transylvanian Museum Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.